Yevgeniy Antipin
Sema4 (United States), Icahn School of Medicine at Mount Sinai
Papers
2
Total Citations
145
H-Index
2
About
Yevgeniy Antipin is a pioneering researcher in personalized oncology, specializing in rare cancers and the use of Drosophila-based platforms for drug discovery. His major contributions center on developing innovative, personalized treatment strategies for patients with limited therapeutic options. Antipin’s most impactful work, a 2019 study with 107 citations, describes a personalized platform that identified the combination of trametinib and zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. Using a robotics-based screen in Drosophila, his team pinpointed this regimen, leading to a significant clinical response with 11 months of stable disease. In a 2021 study (38 citations), he applied a similar Drosophila platform to discover a novel therapy for a patient with adenoid cystic carcinoma, a rare salivary gland cancer notoriously difficult to treat due to perineural invasion. This work highlights his ability to translate preclinical models into actionable, patient-specific treatments. Antipin’s achievements demonstrate the power of personalized medicine and high-throughput screening to address unmet needs in oncology, offering hope for patients with challenging diagnoses.
Research Focus
Key Achievements
Top Papers
- 1
- 2